Harrow to Present Three Clinical Abstracts at ASCRS 2026 Annual Meeting

Event summary

  • Harrow's three abstracts accepted for presentation at ASCRS 2026 Annual Meeting, April 10–13 in Washington, D.C.
  • Abstracts focus on VEVYE® and ILEVRO®, highlighting real-world treatment patterns and clinical outcomes.
  • Presentations scheduled for April 11 and April 12, covering ocular surface disease and postoperative care.
  • ASCRS Annual Meeting is a premier gathering for ophthalmic surgeons and professionals.

The big picture

Harrow's acceptance of three abstracts at ASCRS 2026 underscores its focus on evidence-based treatment options for ophthalmic diseases. The presentations come at a time when the ophthalmology sector is increasingly prioritizing real-world clinical data to differentiate products. Harrow's ability to showcase positive outcomes for VEVYE® and ILEVRO® could enhance its competitive edge in managing dry eye disease and post-cataract surgery complications. The company's strategic emphasis on clinical validation aligns with broader industry trends toward data-driven therapeutic innovations.

What we're watching

Clinical Validation
How the presentation of real-world data will impact market perception of VEVYE® and ILEVRO®.
Product Differentiation
Whether Harrow can leverage these findings to strengthen its position in dry eye disease and post-cataract surgery markets.
Regulatory Compliance
The pace at which Harrow addresses ongoing FDA communications regarding its outsourcing facility in New Jersey.